Pavlos Papakotoulas

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer

G. Stathopoulos, K. Syrigos, Gerasimos Aravantinos et al. · British Journal of Cancer · 2006 · 196 citations · Full text

Medicine, Oncology, Pharmacology +14

Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)

D. Mavroudis, Emmanouil Saloustros, N. Malamos et al. · Annals of Oncology · 2015 · 164 citations

Medicine, Oncology, Breast Oncology +15

Docetaxel Versus Docetaxel Plus Cisplatin As Front-Line Treatment of Patients With Advanced Non—Small-Cell Lung Cancer: A Randomized, Multicenter Phase III Trial

Vassilis Georgoulias, Alexandros Ardavanis, Athina Agelidou et al. · Journal of Clinical Oncology · 2004 · 134 citations · Full text

Medicine, Oncology, Pharmacology +13

Pemetrexed versus erlotinib in pretreated patients with advanced non–small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study

Athanasios Karampeazis, Alexandra Voutsina, John Souglakos et al. · Cancer · 2013 · 112 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Tumor molecular profiling of NSCLC patients using next generation sequencing

Eirini Papadopoulou, Vasiliki Metaxa-Mariatou, Georgios Tsaousis et al. · Oncology Reports · 2017 · 73 citations · Full text

Medicine, Molecular Biology, Oncology +17